濟南高新(600807.SH):全資子公司簽署生物醫藥產業園委託運營合作協議
格隆匯6月5日丨濟南高新(600807.SH)公佈,公司全資子公司濟高生物與關聯方頤誠實業簽署《生物醫藥園中小企業產業化基地項目委託運營合作協議》,濟高生物對頤誠實業擁有的生物醫藥園中小企業產業化基地項目進行運營管理,期限一年,運營管理費以基礎費用+增量獎勵方式結算,其中基礎管理費為500萬元/年,未完成約定租金收入考核的,按照差額比例核減基礎管理費金額,增量部分視超額完成情況進行分檔獎勵。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.